Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Therapeutic drug monitoring in HIV infection: current status and future directions.

Back D, Gatti G, Fletcher C, Garaffo R, Haubrich R, Hoetelmans R, Kurowski M, Luber A, Merry C, Perno CF.

AIDS. 2002 Mar;16 Suppl 1:S5-37. Review.

PMID:
12035820
2.

Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy.

Boffito M, Acosta E, Burger D, Fletcher CV, Flexner C, Garaffo R, Gatti G, Kurowski M, Perno CF, Peytavin G, Regazzi M, Back D.

Antivir Ther. 2005;10(3):375-92. Review.

PMID:
15918329
3.

Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs.

Boffito M, Acosta E, Burger D, Fletcher CV, Flexner C, Garaffo R, Gatti G, Kurowski M, Perno CF, Peytavin G, Regazzi M, Back D.

Antivir Ther. 2005;10(4):469-77. Review.

PMID:
16038472
4.

Therapeutic drug monitoring and the inhibitory quotient of antiretroviral drugs: can they be applied to the current situation?

Ribera E, López-Cortés LF, Soriano V, Casado JL, Mallolas J.

Enferm Infecc Microbiol Clin. 2005 Jul;23 Suppl 2:41-67. Review. English, Spanish.

PMID:
16373004
6.

Improving HIV infection management using antiretroviral plasma drug levels monitoring: a clinician's point of view.

Clevenbergh P, Mouly S, Sellier P, Badsi E, Cervoni J, Vincent V, Trout H, Bergmann JF.

Curr HIV Res. 2004 Oct;2(4):309-21. Review.

PMID:
15544452
7.

Antiretroviral therapy in the year 2000.

Tashima KT, Flanigan TP.

Infect Dis Clin North Am. 2000 Dec;14(4):827-49. Review.

PMID:
11144641
8.

Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.

Fung HB, Stone EA, Piacenti FJ.

Clin Ther. 2002 Oct;24(10):1515-48. Review.

PMID:
12462284
9.

Protease inhibitor plasma concentrations in HIV antiretroviral therapy.

Justesen US.

Dan Med Bull. 2008 Nov;55(4):165-85. Review.

PMID:
19232158
10.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2009 Oct;27(8):491.

PMID:
19246124
11.

Critical issues in therapeutic drug monitoring of antiretroviral drugs.

Van Heeswijk RP.

Ther Drug Monit. 2002 Jun;24(3):323-31. Review.

PMID:
12021621
12.

Therapeutic drug monitoring in the treatment of HIV-infection.

Gerber JG, Acosta EP.

J Clin Virol. 2003 Jul;27(2):117-28. Review.

PMID:
12829033
13.
14.

Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1.

Shehu-Xhilaga M, Tachedjian G, Crowe SM, Kedzierska K.

Curr Med Chem. 2005;12(15):1705-19. Review.

PMID:
16029143
15.

HIV drug interactions: the good, the bad, and the other.

Rainey PM.

Ther Drug Monit. 2002 Feb;24(1):26-31. Review.

PMID:
11805718
16.

Pharmacodynamics and clinical use of anti-HIV drugs.

Preston SL, Piliero PJ, Drusano GL.

Infect Dis Clin North Am. 2003 Sep;17(3):651-74. Review.

PMID:
14711082
17.

Therapeutic drug monitoring in children with HIV/AIDS.

Fraaij PL, Rakhmanina N, Burger DM, de Groot R.

Ther Drug Monit. 2004 Apr;26(2):122-6. Review.

PMID:
15228151
18.

Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment.

Barragan P, Podzamczer D.

Expert Opin Pharmacother. 2008 Sep;9(13):2363-75. doi: 10.1517/14656566.9.13.2363 . Review.

PMID:
18710360
19.

Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy.

Justesen US.

Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):20-31. Review.

20.

Predictors of virologic response to ritonavir-boosted protease inhibitors.

Marcelin AG, Flandre P, Peytavin G, Calvez V.

AIDS Rev. 2005 Oct-Dec;7(4):225-32. Review.

PMID:
16425962

Supplemental Content

Support Center